PROVIDENCE, R.I. — Experienced in both the operating room and research lab, Brown Surgical Associates Steven C. Katz, M.D., FACS is a true innovator in his field. His clinical practice is focused on melanoma, sarcoma, and other complex, rare soft-tissue tumors. His laboratory research endeavors focus on developing novel immunotherapy approaches for liver and pancreas tumors.
He recently discussed what immunotherapy is, and how it helps patients who have tumors that have been deemed inoperable.
Dr. Katz’s overarching career goal is to develop novel immunotherapy treatments for presently incurable liver and pancreas tumors.
“It is a true privilege to join Brown Surgical Associates and be part of a world-class team. I have long admired the leadership and its commitment to serving patients in need of surgical care, in addition to ensuring outstanding medical education programs,” Dr. Katz said. “I look forward to making meaningful contributions in the clinical and academic arenas, including helping the team to provide innovative treatment options which may not be available elsewhere in our region.”
Dr. Katz attended New York University School of Medicine, receiving the Alpha Omega Alpha Award for graduating with the top academic average in his class. He then completed his general surgery residency at the New York University Medical Center. Dr. Katz went on to complete fellowships in immunology and surgical oncology at Memorial Sloan-Kettering Cancer Center, where he served as the chief administrative fellow. As a researcher, he has served as the principal investigator for five solid tumor CAR-T trials, including four for liver metastases and one for peritoneal carcinomatosis. Dr. Katz has developed numerous cell therapy products and methods for solid tumor immunotherapy. He has received research grants from numerous societies, the National Institute of Health, and the Department of Defense, in addition to multiple industry partners.